Eisai Co Ltd Spons A (ESALY) 68.6200 $ESALY
According to analyst, Axovant's RVT-101 could be a blockbuster or maybe not
Seeking Alpha - at Seeking Alpha - Mon Jul 06, 10:28AM CDT
AXON: 17.56 (-0.74), PFE: 34.36 (+0.50), GSK: 42.45 (+0.65)
Sector's Smaller Players Show The Way
EP Vantage - at Seeking Alpha - Sat Jul 04, 11:28AM CDT
With the Nasdaq biotech index proving remarkably resilient to sector-specific and macroeconomic problems alike, smart investors will continue to keep an eye out for signs of panic as a leading indicator of an overall collapse of sentiment. Nothing...
SGYP: 9.13 (+0.49), BIIB: 388.23 (-11.06), ZIOP: 11.17 (+0.69), BMRN: 141.67 (+1.54), PCYC: 261.25 (+1.70), CLDN: 1.26 (+0.01), HSP: 89.15 (+0.02), HRTX: 32.49 (+2.33), ANTH: 8.32 (+0.85), SHPG: 250.34 (+7.35), CLLS: 35.72 (+1.27), RTRX: 33.59 (+1.88), JUNO: 52.05 (+1.72), ABBV: 69.23 (+1.26), AAVL: 16.25 (+0.62), SNY: 51.49 (+2.71), PFE: 34.36 (+0.50), SLXP: 172.96 (+0.15), GSK: 42.45 (+0.65), CELG: 118.84 (+1.97), ISIS: 53.50 (+0.42), TARO: 142.57 (+1.78), PBYI: 106.25 (-2.12), NVS: 103.22 (+3.20)
Why I Am Shorting Axovant
Kanak Kanti De - at Seeking Alpha - Fri Jun 19, 12:51PM CDT
AXON: 17.56 (-0.74), BIIB: 388.23 (-11.06), PFE: 34.36 (+0.50), MRK: 57.95 (+0.57), LLY: 88.29 (+0.81), GSK: 42.45 (+0.65)
Heron Therapeutics: Caveat Emptor
Blue Ridge Buffettologist - at Seeking Alpha - Wed Jun 17, 4:00AM CDT
HRTX: 32.49 (+2.33), TSRO: 58.65 (+1.36), RDHL: 18.46 (+0.11), MRK: 57.95 (+0.57), GSK: 42.45 (+0.65)
Obesity Drugs: Stocks to Watch
George Budwell, The Motley Fool - Motley Fool - Tue Jun 09, 10:06AM CDT
Obesity is a big healthcare problem. In the U.S. alone, an estimated 35% of adults, or 85 million people, are believed to be obese, putting them at increased risk of certain forms of cancer, cardiovascular disease, and type 2 diabetes, among many...
OREX: 4.70 (+0.04), ARNA: 4.29 (+0.04)
Eisai Co's (ESALY) CEO Haruo Naito on Q4 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu May 14, 7:26AM CDT
Arena Pharmaceuticals 1Q Loss Narrower-Than-Expected - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue May 12, 8:10AM CDT
Arena (ARNA) first quarter 2015 results were better-than-expected with the company posting a narrower loss and higher revenues.
GILD: 113.74 (+0.38), ARNA: 4.29 (+0.04)
Jazz Pharmaceuticals Misses on Q1 Earnings, Affirms View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 08, 2:08PM CDT
Jazz Pharmaceuticals (JAZZ) reported first-quarter 2015 earnings of $1.65 per share, substantially lower than the Zacks Consensus Estimate of $1.95.
JAZZ: 178.77 (+2.58), CNCE: 15.71 (+0.27), HPTX: 45.99 (+0.02)
Will Arena Pharmaceuticals (ARNA) Surprise this Earnings? - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu May 07, 3:00PM CDT
Arena (ARNA) will be reporting first quarter 2015 results on May 11.
IPXL: 47.36 (+1.35), ACT: 298.98 (-2.94), ARNA: 4.29 (+0.04)
Will Epizyme (EPZM) Beat Estimates This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 27, 1:40PM CDT
Epizyme, Inc. (EPZM), scheduled to report its first-quarter 2015 results on Apr 28, carries a Zacks Rank #3 with an Earnings ESP of +35.35%.
ACT: 298.98 (-2.94), EPZM: 23.42 (+0.45), EXEL: 3.68 (+0.25)
Arena, Eisai Finish Phase I Studies on Obesity Drug Belviq - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 4:09PM CDT
Arena Pharmaceuticals (ARNA) and Eisai announced the completion of two phase I studies on their obesity drug, Belviq, being developed as a once-daily extended release formulation.
CYTK: 6.10 (+0.02), NVO: 57.68 (+2.91), ARNA: 4.29 (+0.04)
Arena Gets Closer On Extended Release Formulation Of Belviq
Spencer Osborne - at Seeking Alpha - Mon Apr 13, 6:59AM CDT
ARNA: 4.29 (+0.04)
Seeking Alpha's Biotech Weekly: A Biogen Deep Dive, Eisai's Arena Shuffle, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Apr 10, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
BIIB: 388.23 (-11.06), SPHS: 0.78 (+0.03), ADMS: 27.41 (+0.83), TKMR: 11.71 (+0.46), CBYL: 7.26 (+0.31), HPTX: 45.99 (+0.02), QURE: 27.15 (+1.85), SHPG: 250.34 (+7.35), SRPT: 30.02 (+0.66), HZNP: 35.94 (+1.13), GALE: 1.63 (+0.10), JUNO: 52.05 (+1.72), ABBV: 69.23 (+1.26), CBMG: 29.80 (+0.31), ARNA: 4.29 (+0.04), EXEL: 3.68 (+0.25), ADXS: 18.58 (+0.34), PTLA: 46.44 (+1.05), BMY: 69.27 (+1.38), OCUL: 20.82 (+0.73), NVO: 57.68 (+2.91), DVA: 79.30 (+0.48), HALO: 22.78 (+0.38), GILD: 113.74 (+0.38), MRK: 57.95 (+0.57), AZN: 66.45 (+1.90), ALXN: 192.53 (+4.37), NVS: 103.22 (+3.20)
Arena's Partner Eisai Is Slashing Jobs - What Investors Need To Consider
Spencer Osborne - at Seeking Alpha - Fri Apr 10, 9:27AM CDT
OREX: 4.70 (+0.04), ARNA: 4.29 (+0.04)
Arena completes two Phase 1 trials for once-daily formulation of Belviq
Seeking Alpha - at Seeking Alpha - Fri Apr 10, 7:48AM CDT
ARNA: 4.29 (+0.04)
Is Biogen A Buy? An Analysis Of Its Growth Drivers And Challenges
DoctoRx - at Seeking Alpha - Thu Apr 09, 12:28AM CDT
BIIB: 388.23 (-11.06), MDCO: 32.73 (-0.24), GILD: 113.74 (+0.38), MRK: 57.95 (+0.57), AZN: 66.45 (+1.90), LLY: 88.29 (+0.81), ABBV: 69.23 (+1.26), CELG: 118.84 (+1.97)
Arena Pharmaceuticals Up on Belviq's New Patent Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 08, 9:00AM CDT
Arena Pharmaceuticals (ARNA) and Eisai announced that the U.S. Patent and Trademark Office issued a new patent (U.S. Patent No. 8,999,970) to their obesity drug, Belviq.
CYTK: 6.10 (+0.02), NVO: 57.68 (+2.91), ARNA: 4.29 (+0.04)
Merck Inks Deal with Syndax for Cancer Combo Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 01, 5:34PM CDT
Merck (MRK) entered into a collaboration with Syndax to evaluate Keytruda with the latter's entinostat for cancer therapy.
LCI: 59.93 (+2.37), MRK: 57.95 (+0.57), BMY: 69.27 (+1.38)
5 Freakishly Expensive Cancer Drugs
Todd Campbell, The Motley Fool - Motley Fool - Sat Mar 28, 11:03AM CDT
The cost of cancer treatment is climbing, and healthcare advocates are increasingly worrying that skyrocketing cancer medication costs could take a big toll on the healthcare industry in the coming decade. A recent study conducted by the Memorial...
ESRX: 89.75 (+1.84), AMGN: 154.10 (+2.79), LLY: 88.29 (+0.81), NVS: 103.22 (+3.20)
Epizyme's Loss Narrower than Expected, Focus on Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 13, 9:40AM CDT
Epizyme, Inc. (EPZM) reported fourth-quarter 2014 net loss of 44 cents per share, narrower than the Zacks Consensus Estimate of a loss of 54 cents.
CYTK: 6.10 (+0.02), ANIP: 62.22 (+1.36), EPZM: 23.42 (+0.45)
According to analyst, Axovant's RVT-101 could be a blockbuster or maybe not
Seeking Alpha - at Seeking Alpha - Mon Jul 06, 10:28AM CDT
AXON: 17.56 (-0.74), PFE: 34.36 (+0.50), GSK: 42.45 (+0.65)
Sector's Smaller Players Show The Way
EP Vantage - at Seeking Alpha - Sat Jul 04, 11:28AM CDT
With the Nasdaq biotech index proving remarkably resilient to sector-specific and macroeconomic problems alike, smart investors will continue to keep an eye out for signs of panic as a leading indicator of an overall collapse of sentiment. Nothing...
SGYP: 9.13 (+0.49), BIIB: 388.23 (-11.06), ZIOP: 11.17 (+0.69), BMRN: 141.67 (+1.54), PCYC: 261.25 (+1.70), CLDN: 1.26 (+0.01), HSP: 89.15 (+0.02), HRTX: 32.49 (+2.33), ANTH: 8.32 (+0.85), SHPG: 250.34 (+7.35), CLLS: 35.72 (+1.27), RTRX: 33.59 (+1.88), JUNO: 52.05 (+1.72), ABBV: 69.23 (+1.26), AAVL: 16.25 (+0.62), SNY: 51.49 (+2.71), PFE: 34.36 (+0.50), SLXP: 172.96 (+0.15), GSK: 42.45 (+0.65), CELG: 118.84 (+1.97), ISIS: 53.50 (+0.42), TARO: 142.57 (+1.78), PBYI: 106.25 (-2.12), NVS: 103.22 (+3.20)
Why I Am Shorting Axovant
Kanak Kanti De - at Seeking Alpha - Fri Jun 19, 12:51PM CDT
AXON: 17.56 (-0.74), BIIB: 388.23 (-11.06), PFE: 34.36 (+0.50), MRK: 57.95 (+0.57), LLY: 88.29 (+0.81), GSK: 42.45 (+0.65)
Heron Therapeutics: Caveat Emptor
Blue Ridge Buffettologist - at Seeking Alpha - Wed Jun 17, 4:00AM CDT
HRTX: 32.49 (+2.33), TSRO: 58.65 (+1.36), RDHL: 18.46 (+0.11), MRK: 57.95 (+0.57), GSK: 42.45 (+0.65)
Obesity Drugs: Stocks to Watch
George Budwell, The Motley Fool - Motley Fool - Tue Jun 09, 10:06AM CDT
Obesity is a big healthcare problem. In the U.S. alone, an estimated 35% of adults, or 85 million people, are believed to be obese, putting them at increased risk of certain forms of cancer, cardiovascular disease, and type 2 diabetes, among many...
OREX: 4.70 (+0.04), ARNA: 4.29 (+0.04)
Eisai Co's (ESALY) CEO Haruo Naito on Q4 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu May 14, 7:26AM CDT
Arena Pharmaceuticals 1Q Loss Narrower-Than-Expected - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue May 12, 8:10AM CDT
Arena (ARNA) first quarter 2015 results were better-than-expected with the company posting a narrower loss and higher revenues.
GILD: 113.74 (+0.38), ARNA: 4.29 (+0.04)
Jazz Pharmaceuticals Misses on Q1 Earnings, Affirms View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 08, 2:08PM CDT
Jazz Pharmaceuticals (JAZZ) reported first-quarter 2015 earnings of $1.65 per share, substantially lower than the Zacks Consensus Estimate of $1.95.
JAZZ: 178.77 (+2.58), CNCE: 15.71 (+0.27), HPTX: 45.99 (+0.02)
Will Arena Pharmaceuticals (ARNA) Surprise this Earnings? - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu May 07, 3:00PM CDT
Arena (ARNA) will be reporting first quarter 2015 results on May 11.
IPXL: 47.36 (+1.35), ACT: 298.98 (-2.94), ARNA: 4.29 (+0.04)
Will Epizyme (EPZM) Beat Estimates This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 27, 1:40PM CDT
Epizyme, Inc. (EPZM), scheduled to report its first-quarter 2015 results on Apr 28, carries a Zacks Rank #3 with an Earnings ESP of +35.35%.
ACT: 298.98 (-2.94), EPZM: 23.42 (+0.45), EXEL: 3.68 (+0.25)
Arena, Eisai Finish Phase I Studies on Obesity Drug Belviq - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 4:09PM CDT
Arena Pharmaceuticals (ARNA) and Eisai announced the completion of two phase I studies on their obesity drug, Belviq, being developed as a once-daily extended release formulation.
CYTK: 6.10 (+0.02), NVO: 57.68 (+2.91), ARNA: 4.29 (+0.04)
Arena Gets Closer On Extended Release Formulation Of Belviq
Spencer Osborne - at Seeking Alpha - Mon Apr 13, 6:59AM CDT
ARNA: 4.29 (+0.04)
Seeking Alpha's Biotech Weekly: A Biogen Deep Dive, Eisai's Arena Shuffle, And More
SA Editor Mike Taylor - at Seeking Alpha - Fri Apr 10, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
BIIB: 388.23 (-11.06), SPHS: 0.78 (+0.03), ADMS: 27.41 (+0.83), TKMR: 11.71 (+0.46), CBYL: 7.26 (+0.31), HPTX: 45.99 (+0.02), QURE: 27.15 (+1.85), SHPG: 250.34 (+7.35), SRPT: 30.02 (+0.66), HZNP: 35.94 (+1.13), GALE: 1.63 (+0.10), JUNO: 52.05 (+1.72), ABBV: 69.23 (+1.26), CBMG: 29.80 (+0.31), ARNA: 4.29 (+0.04), EXEL: 3.68 (+0.25), ADXS: 18.58 (+0.34), PTLA: 46.44 (+1.05), BMY: 69.27 (+1.38), OCUL: 20.82 (+0.73), NVO: 57.68 (+2.91), DVA: 79.30 (+0.48), HALO: 22.78 (+0.38), GILD: 113.74 (+0.38), MRK: 57.95 (+0.57), AZN: 66.45 (+1.90), ALXN: 192.53 (+4.37), NVS: 103.22 (+3.20)
Arena's Partner Eisai Is Slashing Jobs - What Investors Need To Consider
Spencer Osborne - at Seeking Alpha - Fri Apr 10, 9:27AM CDT
OREX: 4.70 (+0.04), ARNA: 4.29 (+0.04)
Arena completes two Phase 1 trials for once-daily formulation of Belviq
Seeking Alpha - at Seeking Alpha - Fri Apr 10, 7:48AM CDT
ARNA: 4.29 (+0.04)
Is Biogen A Buy? An Analysis Of Its Growth Drivers And Challenges
DoctoRx - at Seeking Alpha - Thu Apr 09, 12:28AM CDT
BIIB: 388.23 (-11.06), MDCO: 32.73 (-0.24), GILD: 113.74 (+0.38), MRK: 57.95 (+0.57), AZN: 66.45 (+1.90), LLY: 88.29 (+0.81), ABBV: 69.23 (+1.26), CELG: 118.84 (+1.97)
Arena Pharmaceuticals Up on Belviq's New Patent Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 08, 9:00AM CDT
Arena Pharmaceuticals (ARNA) and Eisai announced that the U.S. Patent and Trademark Office issued a new patent (U.S. Patent No. 8,999,970) to their obesity drug, Belviq.
CYTK: 6.10 (+0.02), NVO: 57.68 (+2.91), ARNA: 4.29 (+0.04)
Merck Inks Deal with Syndax for Cancer Combo Therapy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 01, 5:34PM CDT
Merck (MRK) entered into a collaboration with Syndax to evaluate Keytruda with the latter's entinostat for cancer therapy.
LCI: 59.93 (+2.37), MRK: 57.95 (+0.57), BMY: 69.27 (+1.38)
5 Freakishly Expensive Cancer Drugs
Todd Campbell, The Motley Fool - Motley Fool - Sat Mar 28, 11:03AM CDT
The cost of cancer treatment is climbing, and healthcare advocates are increasingly worrying that skyrocketing cancer medication costs could take a big toll on the healthcare industry in the coming decade. A recent study conducted by the Memorial...
ESRX: 89.75 (+1.84), AMGN: 154.10 (+2.79), LLY: 88.29 (+0.81), NVS: 103.22 (+3.20)
Epizyme's Loss Narrower than Expected, Focus on Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 13, 9:40AM CDT
Epizyme, Inc. (EPZM) reported fourth-quarter 2014 net loss of 44 cents per share, narrower than the Zacks Consensus Estimate of a loss of 54 cents.
CYTK: 6.10 (+0.02), ANIP: 62.22 (+1.36), EPZM: 23.42 (+0.45)
